Vaccination and other interventions to prevent respiratory syncytial virus (RSV) infection could help reduce antibiotic prescribing and help decrease antibiotic resistance, researchers from the United Kingdom reported yesterday in a preprint study.
A research team from the UK Health Security Agency (HSA), Imperial College London, and Oxford University looked at general practice antibiotic prescribing data and lab-confirmed respiratory infections from 2015 to 2018 to tease out the proportion of antibiotic prescriptions doctors were writing for RSV infections.
They found that about 2.1% of antibiotic prescriptions over that period were connected to RSV diagnosis, with the largest number in people older than 75 and the highest prescribing rate in infants.
Role of vaccines in curbing antibiotic use
Ceire Costelloe, PhD, a visiting professor of health informatics at Imperial College London, said in an HSA press release that the study is the first estimate of RSV-attributable primary care antibiotic prescriptions by antibiotic class using a nationally representative surveillance data. "Importantly, our study suggests that interventions to reduce the burden of RSV infections in England, such as vaccines, could complement current strategies to reduce antibiotic use nationally."
The United Kingdom launched an RSV vaccination program in September, offering the shot to seniors ages 75 to 79 and to pregnant women once they reach 28 weeks gestation. Health officials estimate that the vaccine campaign could avert 70,000 RSV infections in babies younger than 12 months and 60,000 fewer illnesses in older adults.